Carotid atherosclerosis and lectin-like oxidized low density lipoprotein receptor-1 levels in hemodialysis patients

Year 2022, Volume: 8 Issue: 2, 169 - 174, 04.03.2022

Tuncay Dagel , Mehmet Gökhan Gönenli , Serdar Kahvecioğlu

https://doi.org/10.18621/eurj.870716

Abstract

Objectives: Atherosclerotic cardiovascular disease risk is increased in hemodialysis patients. Oxidized low density lipoprotein has an important role in atherosclerotic process and it exerts this effect via lectin like oxidized low density lipoprotein-1 (LOX-1). Carotid artery intima-media thickness (CIMT) is accepted as a god indicator of subclinical atherosclerosis. In this study, we aimed to investigate LOX-1 and CIMT levels in hemodialysis patients.

Methods: Twenty-eight patients treated with hemodialysis at least 6 months and 19 healthy subjects were enrolled in this study. Serum LOX-1 levels and simultaneously with CIMT were measured in hemodialysis patients and healthy control group.

Results: CIMT value was found to be statistically significantly higher in the hemodialysis group compared to control group (0.9 mm in hemodialysis group vs. 0.7 mm in control group, p < 0.001). There was no statistically significant difference between groups in terms of LOX-1 levels. (0.172 ng/ml in hemodialysis group vs. 0.213 ng/ml in healthy control group, p > 0.05).

Conclusions: Although cardiovascular risk markers like CIMT, CRP were higher in hemodialysis group as expected, increase in LOX-1 levels was not detected.

Keywords

Atherosclerosis, Carotid intima-media thickness, Hemodialysis, Lectin-like oxidized low densitiy lipoprotein receptor-1

References

• 1. Hakeem A, Bhatti S, Chang SM. Screening and risk stratification of coronary artery disease in end-stage renal disease. JACC Cardiovasc Imaging 2014;7:715-28.
• 2. Ardhanari S, Alpert MA, Aggarwal K. Cardiovascular disease in chronic kidney disease: risk factors, pathogenesis, and prevention. Adv Perit Dial 2014;30:40-53.
• 3. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 2000;35 (4 suppl 1):S117-31.
• 4. Sarnak MJ, Coronado BE, Greene T, Wang SR, Kusek SW, Beck GJ, et al. Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 2002;57:327-35.
• 5. Zoccali C, Mallamaci F, Tripepi G. Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int Suppl 2003;85:105-10.
• 6. Vecchione L, Gargiu E, Borgiani P, Predazzi I, Mango R, Romeo F, et al. Genotyping OLR1 gene: a genomic biomarker for cardiovascular diseases. Recent Pat Cardiovasc Drug Discov 2007;2:147-51.
• 7. Moriwaki H, Kume N, Kataoka H, Murase T, Nishi E, Sawamura T, et al. Expression of lectin-like oxidized low density lipoprotein receptor-1 in human and murine macrophages: upregulated expression by TNF-α. FEBS Lett 1998;440:29-32.
• 8. Aoyama T, Chen M, Fujiwara H, Masaki T, Sawamura T. LOX-1 mediates lysophosphatidylcholine induced oxidized LDL uptake in smooth muscle cells. FEBS Lett 2000;467:217-20.
• 9. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intimamedia thickness: a systematic review and meta-analysis. Circulation 2007;115:459-67.
• 10. Carpenter M, Sinclair H, Kunadian V. Carotid intima media thickness and its utility as a predictor of cardiovascular disease: a review of evidence. Cardiol Rev 2016;24:70-5.
• 11. Jungers P, Massy ZA, Nguyen Khoa T, Fumeron C, Labrunie M, Lacour B, et al. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study. Nephrol Dial Transplant 1997;12:2597-602.
• 12. Kumar, KS, Lakshmi HY, Rao PVS, Das GC, Kumar VS. Carotid intima-media thickness in patients with end-stage renal disease. Indian J Nephrol 2009;19:13-4.
• 13. Prasad N, Kumar S, Singh A, Sinha A, Chawla K, Gupta A, et al. Carotid intimal thickness and flow-mediated dilatation in diabetic and nondiabetic continuous ambulatory peritoneal dialysis patients. Perit Dial Int 2009;29 Suppl 2:S96-101.
• 14. Puccetti L, Pasqui AL, Bruni F, Pastorelli M, Ciani F, Palazzuoli A, et al. Lectin like oxidized-LDL receptor-1 (LOX-1) polymorphisms influence cardiovascular events rate during statin treatment. Int J Cardiol 2007;25:41-7.
• 15. Sakurai K, Sawamura T. Stress and vascular responses: endothelial dysfunction via lectin-like oxidized low-density lipoprotein receptor-1: close relationships with oxidative stress. J Pharmacol Sci 2003;91:182-6.
• 16. Hayashida K, Kume N, Murase T, Minami M, Nakagawa D, Inada T, et al. Serum soluble lectin like oxidized-LDL receptor-1 levels are elevated in acute coronary syndrome: a novel marker for early diagnosis. Circulation 2005;112:812-8.
• 17. Li D, Chen H, Romeo F, Sawamura T, Saldeen T, Mehta JL. Statins modulate oxidized low-density lipoprotein-mediated adhesion molecule expression in human coronary artery endothelial cells: role of LOX-1. J Pharmacol Exp Ther 2002;302:601-5.
• 18. Sugiyama M, Ohashi M, Takase H, Sato K, Ueda R, Dohi Y. Effects of atorvastatin on inflammation and oxidative stress. Heart Vessels 2005;20:133-6.
• 19. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Fermo I, Foca A, et al. Inflammation is associated with carotid atherosclerosis in dialysis patients. Creed Investigators. Cardiovascular Risk Extended Evaluation in Dialysis Patients. J Hypertens. 2000;18:1207-13.
• 20. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999;55:1899-911.
• 21. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997;349:462-6.
• 22. Owen WF, Lowrie EG. C-reactive protein as an outcome predictor for maintanence hemodialysis patients. Kidney Int 1998;54:627-36.